MedPath

Clinical Trial News

Targeting the Endothelin A Receptor in IgA Nephropathy: A New Therapeutic Approach

Recent advancements in the treatment of IgA Nephropathy (IgAN) focus on targeting the Endothelin-A receptor (ETAR) to mitigate renal deterioration. This approach is based on the understanding that ETAR activation contributes to various pathophysiological effects in the kidney, including vasoconstriction, inflammation, and fibrosis. Clinical trials have shown that ETAR blockade can reduce proteinuria and slow disease progression, offering a promising new avenue for IgAN treatment.

Atrasentan in Patients With Proteinuric Glomerular Diseases

NCT04573920Active, Not RecruitingPhase 2
Novartis Pharmaceuticals
Posted 3/15/2021

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

NCT04663204Active, Not RecruitingPhase 2
University of Leicester
Posted 12/10/2020

NEPTUNE Match Study

NCT04571658Enrolling by Invitation
University of Michigan
Posted 3/1/2021

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986RecruitingPhase 2
Travere Therapeutics, Inc.
Posted 8/12/2021

Atrasentan in Patients With IgA Nephropathy

NCT04573478Active, Not RecruitingPhase 3
Chinook Therapeutics, Inc.
Posted 12/11/2020

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

NCT04724837CompletedPhase 2
AstraZeneca
Posted 4/28/2021

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

NCT05834738Active, Not RecruitingPhase 2
Novartis Pharmaceuticals
Posted 7/20/2023

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850Active, Not RecruitingPhase 3
Travere Therapeutics, Inc.
Posted 12/11/2018

CAGE Bio's Topical Tofacitinib Shows Promise in Phase 2 Atopic Dermatitis Trial

  • CAGE Bio's CGB-500, a topical formulation of 1% tofacitinib, demonstrated a 98% reduction in EASI scores compared to 28% with the vehicle in atopic dermatitis patients.
  • The Phase 2 study achieved all primary and secondary endpoints, with 95% of patients in the active group achieving treatment success versus 24% in the vehicle group.
  • CGB-500 was well-tolerated, with no treatment-emergent adverse events, suggesting a favorable safety profile for localized treatment of immuno-dermatological disorders.
  • CAGE Bio plans to initiate dose ranging and registration trials to further validate the efficacy and safety of CGB-500 for regulatory submissions and potential approval.

Elraglusib Receives FDA Orphan Drug Designation for Pancreatic Cancer Treatment

  • The FDA has granted Orphan Drug Designation to elraglusib, a GSK-3β inhibitor, for the treatment of patients with pancreatic cancer, addressing a high unmet medical need.
  • Elraglusib is currently being evaluated in phase 2 trials, both as a monotherapy and in combination with other agents like gemcitabine and nab-paclitaxel, for advanced pancreatic cancer.
  • The Orphan Drug Designation provides Actuate Therapeutics with benefits including assistance in drug development, tax credits, and potential marketing exclusivity.
  • Elraglusib targets molecular pathways involved in tumor growth and resistance to chemotherapy, showing promise as a novel therapeutic approach for pancreatic cancer.

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

NCT05239182TerminatedPhase 2
Anwaar Saeed
Posted 1/26/2022

9-ING-41 in Patients with Advanced Cancers

NCT03678883Active, Not RecruitingPhase 2
Actuate Therapeutics Inc.
Posted 1/4/2019

FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

NCT05077800RecruitingPhase 2
Colin D. Weekes, M.D., PhD
Posted 3/21/2022

Transcranial Random Noise Stimulation Shows Promise in Pediatric ADHD

  • A clinical trial found that transcranial random noise stimulation (tRNS) combined with cognitive training may alleviate ADHD symptoms in children.
  • 55% of parents reported significant clinical improvement in their children's ADHD symptoms after tRNS treatment, compared to 17% in the placebo group.
  • The study, involving 23 children aged 6-12, suggests tRNS has the potential to become a new therapeutic option for ADHD.
  • Researchers are planning a larger clinical trial, with hopes of FDA approval for tRNS as a medical device for ADHD treatment.

TYRA Biosciences Receives FDA Orphan Drug Designation for TYRA-300 in Achondroplasia

• TYRA Biosciences received FDA Orphan Drug Designation for TYRA-300, an oral FGFR3 selective inhibitor, for treating achondroplasia, the most common form of dwarfism. • TYRA-300 aims to address not only height but also long-term health complications like cranial and spinal stenosis associated with achondroplasia. • A Phase 2 clinical study of TYRA-300 in pediatric achondroplasia is planned for 2024, following positive preclinical results and an upcoming IND submission. • Michael Bober, M.D. Ph.D., a specialist in skeletal dysplasia, has been appointed VP, Clinical Development and Medical Affairs, to lead the TYRA-300 program.

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552RecruitingPhase 1
Tyra Biosciences, Inc
Posted 11/22/2022

AI Cancer Detection Tool Shows 13% Boost in Prostate Cancer Diagnosis, Expands to Breast Cancer Screening in Wales

• The Welsh NHS has reported a 13% increase in prostate cancer detection using the IBEX Galen AI platform during initial pilot studies at Betsi Cadwaladr Health Board.
• The successful AI diagnostic tool will be expanded to five additional health boards across Wales and extended to include breast cancer screening applications.
• The implementation is part of Wales' new digital health strategy, prioritizing AI-powered diagnostics to improve early detection and streamline cancer diagnosis workflows.

Advancements in HCC Treatment: The Role of TACE Combined with Targeted and Immune Therapies

Recent studies highlight the effectiveness of combining Transarterial Chemoembolization (TACE) with molecularly targeted agents and immune checkpoint inhibitors (ICIs) for treating intermediate and advanced Hepatocellular Carcinoma (HCC). This combination therapy shows promising results in improving overall survival (OS) and progression-free survival (PFS) compared to TACE combined with molecularly targeted agents alone. The research underscores the potential of this triple therapy in enhancing the prognosis of HCC patients, despite the need for further investigation into optimal treatment intervals and criteria.

NIH Launches Clinical Trials to Evaluate Long COVID Treatments

• The NIH has initiated clinical trials under the RECOVER initiative to assess potential treatments for long COVID symptoms, addressing a significant unmet medical need. • The RECOVER-VITAL trial will investigate the efficacy of Paxlovid in treating persistent SARS-CoV-2, while RECOVER-NEURO will explore interventions for cognitive dysfunction, including brain fog. • Additional trials, RECOVER-SLEEP and RECOVER-AUTONOMIC, will address sleep disturbances and autonomic nervous system dysfunction, respectively, with plans for an exercise and fatigue study. • These trials represent a crucial step in the comprehensive effort to understand, treat, and prevent long COVID, with the aim of informing clinical care and improving patient outcomes.

Artificial Intelligence Enhances Diagnostic Accuracy in Capsule Endoscopy for Small Bowel Bleeding

A recent study highlights the effectiveness of the AI tool TOP100 in diagnosing suspected overt small bowel bleeding (SBB) through capsule endoscopy, showing high diagnostic accuracy and significantly reduced reading times. The study, conducted at the Hospital Clínic of Barcelona, compared the AI-aided reading with standard reading methods, demonstrating TOP100's potential to rapidly identify significant lesions and prioritize therapeutic interventions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.